ホーム >> Signaling Pathways >> Apoptosis >> c-RET

c-RET

The c-RET proto-oncogene, which was originally identified as a transforming gene by transfection of T-cell lymphoma DNA into NIH3T3 cells, is a member of the receptor tyrosine kinase (RTK) gene superfamily that encodes a receptor tyrosine kinase involved in the regulation of glial cell line-derived neurotrophic factor (GDNF) signaling. Signaling proteins, such as Grb7/Grb10, PLCγ, Shc/Enigma and Grb2, are recruited by activated c-RET protein through binding to the phosphorylated tyrosine residues in c-RET protein’s COOH-terminal sequence, Y905, Y1015, Y1062 and Y1096 respectively.  Moreover, results of in vivo studies suggest mutations of c-RET have been implicated in tumorigenesis, in which c-RET mRNA and/or protein have been found in tumors of neuroectodermal origin as well as in human neuroblastoma cell lines.

製品は  c-RET

  1. Cat.No. 商品名 インフォメーション
  2. GC16362 AD57 (hydrochloride)

    RETを抑制する多剤作用がん治療薬。

    AD57 (hydrochloride)  Chemical Structure
  3. GC16391 Amuvatinib (MP-470, HPK 56)

    HPK56, MP470

    多標的RTK阻害剤

    Amuvatinib (MP-470, HPK 56)  Chemical Structure
  4. GC15217 Danusertib (PHA-739358)

    PHA-739358

    パン・オーロラキナーゼとAbl阻害剤

    Danusertib (PHA-739358)  Chemical Structure
  5. GC14606 Regorafenib hydrochloride

    多機能キナーゼ阻害剤

    Regorafenib hydrochloride  Chemical Structure
  6. GC14534 Regorafenib monohydrate

    多機能キナーゼ阻害剤

    Regorafenib monohydrate  Chemical Structure
  7. GC13194 RPI-1 RPI-1 は、特定の経口投与可能な 2-インドリノン Ret チロシンキナーゼ阻害剤です。 RPI-1 は、ヒト甲状腺髄様癌 TT 細胞の増殖、Ret チロシンリン酸化、Ret タンパク質発現、および PLCgamma、ERK、AKT の活性化を阻害します。抗腫瘍活性。 RPI-1  Chemical Structure
  8. GC15307 SU5416

    NSC 696819, Semaxinib, Sugen 5416, VEGFR 2 Kinase Inhibitor

    チロシンキナーゼ阻害剤

    SU5416  Chemical Structure
  9. GC10035 TG101209

    JAK2、FLT3、RET、およびJAK3の阻害剤

    TG101209  Chemical Structure

8 アイテム

降順